Verrica YCANTH Units Up 12.1%; COVE-3 Trial Start Mid-2026 $VRCA

Verrica Pharmaceuticals (VRCA) reported first-quarter 2026 results that included a 12.1% sequential increase in dispensed units of its lead product, YCANTH (cantharidin) topical solution. The company also set a target to initiate the COVE-3 Phase III trial for common warts by mid-2026. The update, delivered during the earnings call, framed the next leg of the commercial and clinical story for the dermatology-focused biotech.

YCANTH Dispensed Units Rise 12.1% Sequentially

YCANTH, approved for the treatment of molluscum contagiosum, recorded a 12.1% sequential rise in dispensed units during Q1 2026. The company described demand as reaching a record level. The sequential growth suggests that the commercial launch is gaining traction with prescribers and patients. Verrica did not disclose absolute dispensed unit figures, focusing instead on the sequential growth rate.

Molluscum contagiosum is a common viral skin infection that primarily affects children, with an estimated 6 million cases annually in the U.S. YCANTH is the first FDA-approved in-office treatment, offering a non-invasive alternative to physical destruction methods. The sequential unit increase points to expanding adoption, a metric that investors track as a proxy for revenue momentum. Verrica did not break out net revenue per unit. The volume gain alone provides a positive demand signal. The next quarterly report will provide a fuller financial picture.

COVE-3 Initiation by Mid-2026 Sets Next Clinical Milestone

Verrica plans to initiate the COVE-3 Phase III study for common warts by mid-2026. The trial would expand the YCANTH label beyond molluscum, targeting a much larger dermatology market. Common warts affect millions of patients and are caused by human papillomavirus (HPV), representing one of the most frequent dermatological complaints. An in-office, non-surgical treatment could capture meaningful share if clinical data support efficacy and safety. Current common wart treatments include cryotherapy and topical salicylic acid, which often require multiple visits. An in-office cantharidin application could offer a single-session alternative.

The mid-2026 initiation target gives the market a concrete timeline to monitor. Phase III trials for dermatology indications typically enroll over several quarters, so the first data readout would likely be a 2027 or 2028 event. The company did not provide specific enrollment targets or trial design details. The commitment to a near-term start signals confidence in the regulatory pathway and the underlying cantharidin platform.

Japan Launch and EU Path Extend Revenue Map

Beyond the U.S. commercial ramp, Verrica is advancing a launch in Japan and progressing along a regulatory path in the European Union. The Japan launch represents the first international commercialization of YCANTH, opening a new revenue stream. Japan's dermatology market is substantial, with a strong preference for in-office procedures. The EU path, while still in development, would further diversify the geographic footprint. The EU regulatory process typically involves a centralized marketing authorization application, with a timeline of 12-18 months once submitted.

International expansion matters for a single-product biotech because it reduces reliance on U.S. payer dynamics and prescription trends. The company did not quantify expected contributions from Japan or the EU, so the near-term financial impact remains uncertain. The market will look for initial prescription data from Japan as a signal of ex-U.S. demand.

Cash Runway and the Next Decision Point

Verrica discussed its cash runway during the call, indicating that current resources are sufficient to fund operations through key clinical and commercial milestones. Management's commentary implies that the company can reach the COVE-3 initiation without additional financing. The absence of a pressing financing overhang may reduce immediate dilution risk. The next concrete catalyst for VRCA is the actual initiation of COVE-3 by mid-2026. Updates on Japan launch metrics and EU regulatory progress will also shape the stock's trajectory. For broader context on biotech catalysts, see stock market analysis. The 12.1% sequential unit growth provides a positive demand signal. Sustained commercial execution and pipeline delivery will determine whether the stock can re-rate from current levels.